Stock Market & Financial Investment News

News Breaks January 4, 2013 13:21 EDT MNOV MedicNova price target lowered to $6 from $10.50 at Ladenburg Ladenburg reduced its target on MedicNova after the company indicated that the FDA would require the company to show through a Phase III trial that its asthma treatment reduces hospitalizations. However, the firm continues to be upbeat on the stock and maintains a Buy rating. News For MNOV From The Last 14 Days Check below for free stories on MNOV the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 16:29 EDT MNOV Satomi Hajime reports 10% passive stake in MedicNova Subscribe for More Information May 9, 2013 10:01 EDT MNOV MedicNova falls 21.6% MedicNova is down 21.6%, or $1.00, to $3.63 May 8, 2013 17:33 EDT MNOV MedicNova reports Q1 EPS (14c), one estimate (13c) Sign up for a free trial to see the rest of the stories you've been missing.